DDM-058 - Combined blockade of lipid uptake and synthesis by CD36Inhibitor and SCD1 siRNA Is beneficial for the treatment of refractory prostate cancer

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: DDM-058
• By: YUAN, Yongfang (Department of Pharmacy, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School Of Medicine, China)
• Co-author(s): Yongfang Yuan (Department of Pharmacy, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School Of Medicine, Shanghai, China)
  
• Abstract:

  Introduction: Drug resistance is a key factor in the progression of prostate cancer (PCa) to refractory PCa, and abnormal lipid metabolism frequently occurs in refractory PCa. These abnormalities can affect biological functions such as proliferation, metastasis, and drug resistance in PCa, thereby exacerbating the progression and spread of PCa and ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login